Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CGONCg Oncology Inc | $134.0M | 22.1% | +2389.8% |
| TNGXTango Therapeutics Inc | $95.7M | 15.8% | +543.0% |
| RVMDRevolution Medicines Inc | $45.3M | 7.5% | +199.6% |
| Pharvaris N VCUSIP N69605108 | $26.8M | 4.4% | +348.4% |
| LQDALiquidia Corporation | $20.5M | 3.4% | +36.6% |
| ELVNEnliven Therapeutics Inc | $18.5M | 3.1% | +122.8% |
| ABVXAbivax Sa | $14.8M | 2.4% | +158.6% |
| AVTXAvalo Therapeutics Inc | $14.2M | 2.4% | +260.5% |
| MIRMMirum Pharmaceuticals Inc | $12.9M | 2.1% | New |
| ASMBAssembly Biosciences Inc | $11.9M | 2.0% | +671.5% |
| IPSCCentury Therapeutics Inc | $10.7M | 1.8% | +47.5% |
| CYTKCytokinetics Inc | $10.1M | 1.7% | +93.0% |
| TSHATaysha Gene Therapies Inc | $9.9M | 1.6% | +140.4% |
| MANEVeradermics Inc | $9.8M | 1.6% | New |
| AVBPArrivent Biopharma Inc | $8.6M | 1.4% | +390.7% |
| TARSTarsus Pharmaceuticals Inc | $7.9M | 1.3% | +491.2% |
| XNCRXencor Inc | $7.8M | 1.3% | +360.4% |
| Roivant Sciences LtdCUSIP G76279101 | $7.8M | 1.3% | +71.7% |
| Damora Therapeutics IncCUSIP 36322Q206 | $7.4M | 1.2% | +180.9% |
| AXSMAxsome Therapeutics Inc | $7.1M | 1.2% | +105.1% |
| DFTXDefinium Therapeutics Inc | $7.0M | 1.2% | +48.8% |
| DNTHDianthus Therapeutics Inc | $6.3M | 1.0% | +19.3% |
| COGTCogent Biosciences Inc | $5.7M | 0.9% | −1.3% |
| ERASErasca Inc | $5.6M | 0.9% | +38.5% |
| PTGXProtagonist Therapeutics Inc | $5.6M | 0.9% | +1035.0% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| TNGXTango Therapeutics Inc | December 31, 2025 | +252.8% | $95.7M |
| ELVNEnliven Therapeutics Inc | December 31, 2025 | +229.5% | $18.5M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $7.0M |
| DNTHDianthus Therapeutics Inc | December 31, 2025 | +136.5% | $6.3M |
| RVMDRevolution Medicines Inc | December 31, 2025 | +135.1% | $45.3M |
| LQDALiquidia Corporation | December 31, 2025 | +131.2% | $20.5M |
| RLAYRelay Therapeutics Inc | December 31, 2025 | +121.2% | $3.3M |
| CGONCg Oncology Inc | December 31, 2025 | +71.1% | $134.0M |
| AVBPArrivent Biopharma Inc | March 31, 2026 | +50.6% | $8.6M |
| PTGXProtagonist Therapeutics Inc | December 31, 2025 | +40.3% | $5.6M |
Sold off last quarter
- Cg Oncology IncCUSIP 156944101 was $97.4M
- TYRATyra Biosciences Inc was $7.5M
- Tango Therapeutics IncCUSIP 87583X110 was $6.3M
- Avalo Therapeutics IncCUSIP 05338F307 was $5.4M
- Minerva Neurosciences IncCUSIP 603380206 was $5.4M
- Pharvaris N VCUSIP N69605109 was $4.1M
- Soleno Therapeutics IncCUSIP 834203309 was $3.9M
- Enliven Therapeutics IncCUSIP 29337E103 was $3.7M
- Cytomx Therapeutics Inc.CUSIP 23284F106 was $3.4M
- Century Therapeutics IncCUSIP 15673T101 was $3.2M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| March 31, 2026 | +32.6% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Seven Fleet Capital Management LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2092021&type=13F-HR&dateb=&owner=include&count=40CIK 2092021
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2092021/000101359426000921/Filed August 17, 2026 · accession 0001013594-26-000921